As per MRFR analysis, the China Plasma Fractionation Market Size was estimated at 1.7 (USD Billion) in 2024.The China Plasma Fractionation Market Industry is expected to grow from 3(USD Billion) in 2025 to 6 (USD Billion) by 2035. The China Plasma Fractionation Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).
Key China Plasma Fractionation Market Trends Highlighted
The China Plasma Fractionation Market is experiencing significant growth, driven by an increasing demand for immunoglobulins and a rising prevalence of chronic diseases. With China's aging population, there is a heightened focus on healthcare solutions, particularly for conditions requiring plasma-derived therapies. The government has been actively promoting initiatives to strengthen blood collection systems and improve the safety and quality of plasma products.
This government support is crucial as it encourages investments in advanced technologies for plasma fractionation, leading to improved efficiency and effectiveness in product yield. Opportunities in the China Plasma Fractionation Market are expanding as local players explore collaborations with global manufacturers to enhance their capabilities.There is a call for the establishment of more plasma collection centers across various provinces, which can help meet the growing domestic demand for plasma-derived therapies.
Additionally, advancements in biotechnology are paving the way for innovative therapies based on plasma, creating a fertile ground for research and development. Companies are now focusing on utilizing these advancements to produce specialized immunoglobulin drugs, which opens new avenues for market expansion. Recent trends highlight an increased emphasis on high-quality plasma products and compliance with international standards.
In particular, as China aims to elevate its role in the global healthcare landscape, there is a push towards meeting stringent regulations that govern the plasma fractionation industry.This move not only ensures the safety of products but also fosters international partnerships. Overall, the China Plasma Fractionation Market reflects a dynamic landscape influenced by healthcare policy, technological advancements, and a growing focus on patient needs.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
China Plasma Fractionation Market Drivers
Increased Demand for Immunoglobulins
The demand for immunoglobulins, crucial in treating immune deficiencies, has been escalating in China. The National Health Commission of the People's Republic of China reported that over 2 million people are diagnosed with primary immune deficiencies annually. This rising prevalence has significantly driven the growth of the China Plasma Fractionation Market Industry, as immunoglobulins are primarily derived from human plasma.
Organizations such as the Chinese Society of Blood Transfusion have noted a staggering 25% growth in immunoglobulin usage over the past five years, further indicating the growing reliance on these treatments.The increase in awareness and diagnosis of immunological disorders propels plasma fractionation as manufacturers strive to meet this surging demand, paving the way for advancements in processing technology and thereby expanding market opportunities within China.
Supportive Government Policies
China's government has been increasingly supportive of the biotechnology sector, particularly in blood product research and production. Recent policies have aimed at enhancing healthcare standards and ensuring the availability of life-saving blood products, including plasma-derived therapies. The Ministry of Health in China has set out clear guidelines and incentives for plasma collection and utilization in the healthcare system. This has resulted in an increase in licensed plasma collection facilities, contributing positively to the China Plasma Fractionation Market Industry.Reports indicate that in 2023 alone, the establishment of new facilities rose by approximately 15%, thereby ensuring a robust supply chain for plasma and enhancing the overall market growth potential.
Technological Advancements in Plasma Fractionation
Innovations in plasma fractionation technologies have been pivotal in enhancing efficiency and output. Companies like Shanghai RAAS Blood Products Co., Ltd. have invested heavily in Research and Development (R&D) to improve the safety and efficacy of plasma-derived products. The introduction of continuous flow technologies and high-yield extraction methods has increased plasma processing capacity significantly. The China Food and Drug Administration reported that such advancements have reduced processing times by approximately 30% in recent years.
This transformation helps to increase the production volumes and, at the same time, meets the growing quality requirements of the customers in the China Plasma Fractionation Market Industry, which leads to significant growth of the market.
Rising Incidences of Chronic Diseases
The prevalence of chronic diseases such as diabetes and cardiovascular disorders in China is contributing to the expansion of the China Plasma Fractionation Market Industry. According to the Chinese Center for Disease Control and Prevention, around 11% of the population suffers from diabetes, leading to an increased need for immunotherapies, which often involve plasma derivatives. This scenario calls for a proportional increase in plasma fractionation to supply essential treatments.As healthcare systems adapt to cater to these increasing numbers, manufacturers in the plasma fractionation industry are expected to see significant growth opportunities as they work to fulfill the demand for chronic disease management, making it a vital market driver.
China Plasma Fractionation Market Segment Insights
Plasma Fractionation Market Product Type Insights
The China Plasma Fractionation Market is witnessing notable developments within its Product Type segment, which includes various crucial components such as Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors. Immunoglobulin, being essential for the treatment of immunodeficiencies and autoimmune diseases, continues to significantly shape the market landscape. The increasing prevalence of such conditions in China has led to a subsequent rise in demand for Immunoglobulin, establishing it as a leading product type within the market.Albumin, another vital product, plays a key role in critical care and surgical settings, often used for fluid replacement and maintaining oncotic pressure, thereby highlighting its importance in the healthcare sector.
As healthcare facilities expand and adopt advanced therapeutic techniques, the demand for Albumin to grow, showcasing its significance in managing various clinical scenarios. Coagulation Factors are integral in treating hemophilia and other bleeding disorders. Their importance is underscored by increasing awareness and diagnosis of such conditions, along with enhanced treatment protocols in China.Consequently, the rising incidence of clotting factor deficiencies has prompted healthcare providers to focus more on the availability and accessibility of these treatments.
On the other hand, Protease Inhibitors are gaining attention due to their role in managing HIV and certain types of viral infections. With a substantial portion of the population affected by these health issues, the demand for Protease Inhibitors rises, ultimately contributing to the overall market growth. The continuous advancements in technology related to plasma fractionation have also paved the way for improved product offerings, enabling manufacturers to cater effectively to the evolving needs of the healthcare sector.
The collaboration between regulatory bodies and industry players has further strengthened the market infrastructure, ensuring that patients have access to high-quality plasma-derived therapies. As the industry progresses, significant opportunities arise, particularly around product innovation and improved plasma processing techniques, which are likely to shape the future dynamics of the China Plasma Fractionation Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plasma Fractionation Market Application Insights
The Application segment of the China Plasma Fractionation Market plays a crucial role in driving market growth, as it encompasses various fields such as Neurology, Hematology, General Medicine, and Immunology. Neurology applications utilize plasma-derived products to treat neurological disorders, reflecting the increasing demand for innovative therapies in China's aging population. In Hematology, the use of plasma fractions for treating blood disorders showcases the necessity of effective treatment solutions.
Meanwhile, General Medicine applications highlight the versatility of plasma products in enhancing patient care across multiple medical disciplines.Immunology remains a significant domain, focusing on immune therapies that are gaining traction in the healthcare landscape, driven by the rising prevalence of autoimmune diseases in China. The growing investments in Research and Development, coupled with supportive government initiatives, further underline the potential for advancements within these applications, paving the way for improved healthcare outcomes and contributing to the overall China Plasma Fractionation Market development. The competitive landscape is also influenced by the increasing number of collaborations and partnerships among industry players aimed at enhancing product offerings and market reach.
Plasma Fractionation Market End User Insights
The China Plasma Fractionation Market is experiencing growth, driven by its diverse ser landscape which includes Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals are crucial as they serve as primary sites for plasma-derived therapies, addressing patient needs for various medical conditions. The presence of a growing aging population in China further amplifies the demand for plasma products in inpatient settings.
Ambulatory Surgical Centers are also significant, as they offer outpatient services that can enhance efficiency and reduce costs in plasma treatment administration.Blood Banks play a vital role in plasma donation and storage, thus directly impacting the availability of plasma-derived products, while Pharmaceutical Companies drive innovation and development in therapeutic solutions, ensuring a consistent supply through Research and Development investments.
This diverse segmentation allows the market to leverage unique growth opportunities, aligning with wider trends such as increased awareness of plasma therapies and investments in biopharmaceuticals, ensuring sustained market progress in the region. The regulatory environment in China also supports advancements in the plasma sector, helping establishments navigate compliance efficiently, which is essential for market growth.
Plasma Fractionation Market Technology Insights
The China Plasma Fractionation Market is experiencing significant growth in the Technology segment, driven by advancements in methodologies essential for effective plasma separation and purification. Among these methodologies, Centrifugation stands out as a widely adopted technique due to its efficiency in separating plasma components based on density differences. Chromatography is also gaining traction, recognized for its ability to achieve high specificity and purity, thereby enhancing product quality. Meanwhile, Precipitation methods are valued for their simplicity and cost-effectiveness, catering to different scale operations within laboratories and industrial settings.
Filtration techniques are critical in ensuring the removal of contaminants and achieving yield recovery rates in plasma fractions, making them vital for the production process. The interplay among these technologies not only boosts the overall efficacy of the plasma fractionation process but also aligns with the growing demand for blood-derived therapies across China, driven by an increasing prevalence of chronic diseases and the need for novel therapeutic solutions. As the industry evolves, these technologies play a significant role in meeting regulatory standards and improving the therapeutic effectiveness of plasma-derived products, thereby addressing both market challenges and consumer needs.
China Plasma Fractionation Market Key Players and Competitive Insights
The China Plasma Fractionation Market has been witnessing significant growth due to the increasing demand for immunoglobulin products and rising awareness related to plasma-derived therapies. With a vast population and a developing healthcare infrastructure, the market presents numerous opportunities for both domestic and international companies. The competitive landscape is characterized by the presence of established players and new entrants striving to enhance their market positions through innovation and strategic alliances. The growing aging population in China, alongside the prevalence of chronic diseases, is propelling the need for plasma derivatives, leading to intensified competition among key market participants.
Octapharma's presence in the China Plasma Fractionation Market is notable as the company continues to position itself as a leader in developing and providing high-quality human protein products. With a strong emphasis on research and development, Octapharma has been able to deliver a range of innovative plasmapheresis and immunotherapy products that cater to various medical needs. The company has built a robust distribution network throughout the region, gaining a competitive edge through its commitment to quality and regulatory compliance. Additionally, Octapharma leverages its global expertise and local knowledge to adapt its offerings to meet the specific requirements of the Chinese market, which strengthens its foothold in this rapidly evolving sector.
Hualan Biological Engineering has emerged as a significant player in the China Plasma Fractionation Market, focusing on the production of immunoglobulins, coagulation factors, and other plasma-derived products. The company is known for its strong operational capabilities, modern production facilities, and dedication to research and development. Hualan has established a commendable market presence through strategic collaborations and partnerships aimed at enhancing its product range and increasing its distribution channels within China.
Strengthened by a solid pipeline of products and a commitment to quality, Hualan is well-positioned to capitalize on the growing demand for plasma-derived therapies. The company's strategic mergers and acquisitions have further bolstered its capabilities, enabling it to expand its market share while continually improving its service offerings in the competitive arena of plasma fractionation.
Key Companies in the China Plasma Fractionation Market Include
China Plasma Fractionation Market Industry Developments
In recent developments, the China Plasma Fractionation Market has seen notable activity, particularly with companies like Octapharma increasing their manufacturing capacity to meet rising domestic demand. Hualan Biological Engineering has made strides in expanding its portfolio of plasma-derived therapies, further solidifying its position in the market. Grifols has announced collaborations aimed at enhancing Research and Development initiatives in China, responding to the country's growing healthcare needs. Meanwhile, CSL Limited has reported a significant growth in market valuation, positively impacting their operational expansion within China.
Kedrion S.p.A has also engaged in strategic partnerships to boost its market presence. Noteworthy mergers include Zhejiang Hisun Pharmaceutical acquiring a smaller biotech firm in September 2023 to broaden its product offerings in the plasma sector and Shanghai RAAS Blood Products aiming at further integration into supply chains through investments in local production facilities last year. The overall market has been positively influenced by government policies promoting advancements in biotechnology, emphasizing blood product safety and production efficiency. These developments underline a rapidly evolving landscape characterized by increased local investment and collaborative efforts among key players in the China Plasma Fractionation Market.
China Plasma Fractionation Market Segmentation Insights
Plasma Fractionation Market Product Type Outlook
Plasma Fractionation Market Application Outlook
Plasma Fractionation Market End User Outlook
Plasma Fractionation Market Technology Outlook
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 1.7 (USD Billion) |
| MARKET SIZE 2024 | 3.0 (USD Billion) |
| MARKET SIZE 2035 | 6.0 (USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.504% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Octapharma, Hualan Biological Engineering, Grifols, CSL Limited, Kedrion S.p.A, Zhejiang Hisun Pharmaceutical, Baxter International, Human Biologics, Pfizer, Shanxi Eryuan Biotech, China National Pharmaceutical Group, Sichuan Yuanda Shuyang Pharmaceutical, Shanghai RAAS Blood Products |
| SEGMENTS COVERED | Product Type, Application, End User, Technology |
| KEY MARKET OPPORTUNITIES | Increasing demand for immunoglobulins, Rising prevalence of hemophilia disorders, Advancements in plasma collection technology, Growing healthcare infrastructure investments, Expanding applications in autoimmune diseases |
| KEY MARKET DYNAMICS | Rising demand for immunoglobulins, Increasing prevalence of hemophilia, Advancements in separation technologies, Growing government support, Expanding healthcare infrastructure |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The China Plasma Fractionation Market is expected to be valued at 3.0 USD Billion in 2024.
By 2035, the China Plasma Fractionation Market is projected to reach a value of 6.0 USD Billion.
The expected CAGR for the China Plasma Fractionation Market from 2025 to 2035 is 6.504%.
In 2024, Immunoglobulin is valued the highest at 1.2 USD Billion within the China Plasma Fractionation Market.
The market for Albumin is expected to reach 1.8 USD Billion by 2035.
Major players in the market include Octapharma, Grifols, CSL Limited, and Baxter International.
The expected market value for Coagulation Factors in 2024 is 0.6 USD Billion.
There are opportunities for growth driven by increasing demand for plasma-derived therapies and rising awareness of immunotherapy.
Challenges may include regulatory hurdles and competition from alternative therapies.
The growth rate of the China Plasma Fractionation Market is expected to be robust compared to other regions due to increasing healthcare investment.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
